Tempus AI, Inc. $TEM Shares Sold by Royal Bank of Canada

Royal Bank of Canada lessened its stake in shares of Tempus AI, Inc. (NASDAQ:TEM) by 62.9% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 26,828 shares of the company’s stock after selling 45,555 shares during the quarter. Royal Bank of Canada’s holdings in Tempus AI were worth $1,212,000 at the end of the most recent reporting period.

Several other large investors have also modified their holdings of the stock. Pictet Asset Management Holding SA grew its position in shares of Tempus AI by 291.3% in the 4th quarter. Pictet Asset Management Holding SA now owns 48,488 shares of the company’s stock valued at $2,948,000 after buying an additional 36,096 shares during the last quarter. Bogart Wealth LLC lifted its position in Tempus AI by 365,087.5% in the fourth quarter. Bogart Wealth LLC now owns 58,430 shares of the company’s stock valued at $3,450,000 after acquiring an additional 58,414 shares during the last quarter. Eagle Health Investments LP acquired a new position in Tempus AI in the first quarter valued at $11,588,000. Alethea Capital Management LLC acquired a new position in Tempus AI in the fourth quarter valued at $1,863,000. Finally, Hussman Strategic Advisors Inc. grew its holdings in shares of Tempus AI by 100.0% during the fourth quarter. Hussman Strategic Advisors Inc. now owns 42,000 shares of the company’s stock worth $2,480,000 after purchasing an additional 21,000 shares during the last quarter. Institutional investors and hedge funds own 24.22% of the company’s stock.

Insider Activity

In other Tempus AI news, EVP Andrew Polovin sold 7,927 shares of the company’s stock in a transaction on Wednesday, August 19th. The shares were sold at an average price of $56.00, for a total transaction of $443,912.00. Following the completion of the transaction, the executive vice president owned 138,140 shares in the company, valued at approximately $7,735,840. This represents a 5.43% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CAO Ryan M. Bartolucci sold 6,175 shares of the firm’s stock in a transaction on Tuesday, August 18th. The stock was sold at an average price of $49.61, for a total transaction of $306,341.75. Following the completion of the sale, the chief accounting officer owned 67,866 shares of the company’s stock, valued at $3,366,832.26. This trade represents a 8.34% decrease in their position. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last quarter, insiders sold 943,202 shares of company stock valued at $46,417,587. 24.26% of the stock is currently owned by company insiders.

Key Headlines Impacting Tempus AI

Here are the key news stories impacting Tempus AI this week:

• Positive Sentiment: BTIG raised its price target to $80 from $70 and maintained a “Buy” rating, implying roughly 20% upside from the referenced price. The upgrade provided a direct catalyst for investor buying. BTIG raises Tempus AI price target
• Positive Sentiment: Investor attention is focusing on Tempus AI’s approximately $1.5 billion stock-based agreement to acquire Personalis. The deal is increasingly viewed as strategically valuable because Personalis’ genomic data and cancer-testing capabilities could strengthen Tempus’ precision-medicine and drug-development platform. Tempus AI biotech deal attracts investor attention
• Positive Sentiment: Moderna’s reported cancer-vaccine progress, alongside developments involving Merck, has encouraged investors to believe Tempus’ Personalis acquisition could benefit from increased demand for genomic data and personalized cancer treatment. The connection is indirect, but it has improved sentiment around Tempus’ strategic positioning. Tempus AI stock rises after Merck-Moderna cancer vaccine breakthrough
• Positive Sentiment: The rally was accompanied by unusually high options activity, with investors buying 40,671 call contracts—about 57% above average daily call volume—signaling increased bullish speculation and potentially reinforcing upward momentum.
• Neutral Sentiment: Technical factors also contributed: TEM moved above key moving averages, while coverage characterized the move as a possible short squeeze. These conditions can accelerate gains but may also increase volatility. Tempus AI stock technical rally

Analyst Upgrades and Downgrades

A number of research firms have recently commented on TEM. Guggenheim lifted their target price on Tempus AI from $60.00 to $65.00 and gave the stock a “buy” rating in a research report on Thursday, July 16th. Stifel Nicolaus decreased their target price on Tempus AI from $60.00 to $50.00 and set a “hold” rating for the company in a research report on Monday, August 3rd. TD Cowen restated a “buy” rating on shares of Tempus AI in a research note on Wednesday, July 15th. Needham & Company LLC reaffirmed a “buy” rating and set a $75.00 price target on shares of Tempus AI in a research report on Friday, July 31st. Finally, Piper Sandler reduced their price objective on Tempus AI from $58.00 to $56.00 and set a “neutral” rating for the company in a research note on Tuesday, August 4th. Nine research analysts have rated the stock with a Buy rating, six have given a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $65.69.

Tempus AI Stock Up 8.8%

TEM opened at $66.65 on Friday. Tempus AI, Inc. has a 52 week low of $40.77 and a 52 week high of $104.32. The business has a 50 day moving average price of $52.44 and a two-hundred day moving average price of $51.21. The company has a quick ratio of 3.16, a current ratio of 3.30 and a debt-to-equity ratio of 3.06. The company has a market cap of $12.03 billion, a PE ratio of -46.28 and a beta of 3.58.

Tempus AI (NASDAQ:TEM) last announced its earnings results on Thursday, July 30th. The company reported ($0.04) earnings per share for the quarter, beating the consensus estimate of ($0.14) by $0.10. The company had revenue of $382.49 million for the quarter, compared to the consensus estimate of $379.69 million. Tempus AI had a negative return on equity of 50.28% and a negative net margin of 17.77%.The company’s revenue was up 21.6% on a year-over-year basis. During the same period last year, the business posted ($0.22) EPS. As a group, research analysts anticipate that Tempus AI, Inc. will post -1.38 EPS for the current year.

About Tempus AI

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.